ViiV Healthcare Presents Results of GSK3640254 (GSK’254) in P-IIa study for the Treatment of HIV at CROI

 ViiV Healthcare Presents Results of GSK3640254 (GSK’254) in P-IIa study for the Treatment of HIV at CROI

ViiV Healthcare Presents Results of GSK3640254 (GSK’254) in P-IIa study for the Treatment of HIV at CROI

Shots:

  • The P-IIa POC study involves assessing GSK3640254 (GSK’254, qd) in 34 treatment-naïve adults with HIV. The study is divided into 2 parts- in part 1, patients received GSK’254 (10/200mg) vs PBO for 10days and in part 2, patients got GSK’254 (40/80140 mg) vs PBO for 7days
  • The study showed the antiviral activity b/w dose and antiviral response with 140 & 200mg doses demonstrating the reduction in plasma HIV-1 RNA. The largest mean changes in viral load were -1.5 log10 & -2.0 log10 copies/ml with these doses respectively
  • These findings support its P-IIb study that evaluates GSK’254 as part of combination therapy for treatment naïve adults living with HIV

Click here ­to­ read full press release/ article | Ref: ViiV Healthcare | Image: ViiV Healthcare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post